CIRG
 |
|
|
 |
Home
3rd analysis of BCIRG 006 presented by Dr Slamon on December 12 at the 2009 SABCS conference (GENERAL SESSION 5 -Exhibit Hall D)
Click here to access the official BCIRG 006 Presentation in pdf format (Slides set in jpg format - zipped file) 2nd analysis of CIRG/TORI 010 study presented at the 2009 SABCS conference by Dr John Mackey from the Cross cancer Institute , abstract 47 CIRG/TORI 010: First Analysis of a Randomized Phase II Trial of Motesanib Plus Weekly Paclitaxel (P) as First Line Therapy in HER2-Negative Metastatic Breast Cancer (MBC)
Abstract 62. Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC -> T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC -> TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study
Click here to access the official CIRG/TORI 010 Presentation
-
For information on new TRIO-CIRG studies please click in the Studies Summary on left side menu.
________________________________________________________
-
CIRG Paris office has moved to a new location, please note our new address:
CIRG - Biopark - 11, rue Watt 75013 Paris France
________________________________________________________
-
SABCS 2007, Dec 13 Dr Slamon presented: "Role of anthracycline -based therapy in the adjuvant treatment of breast cancer: efficacy analyses determined by molecular subtypes of the disease" [abs. 13].
Slamon D, Mackey J, Robert N, Crown J, Martin M, Eiermann W, Pienkowski T, Bee V, Taupin H, Villalobos, Lindsay MA, Riva A, Hurvitz S, Glaspy J, Pauletti G, Sauter G, Press M, CIRG Edmonton Alberta Canada .
Poster presented by Dr. Au from the Cross Cancer Institute in Edmonton Alberta (Canada) [Abs. 3064] :
"BCIRG 006: Quality of life of patients treated with docetaxel and trastuzumab-based regimens in node positive and high risk node negative HER2 positive early breast cancer"Heather-Jane Au, N Robert, W Eiermann, T Pienkowski, J Crown, M Martin, M Pawlicki, A Chan, V Bee and D Slamon. Breast Cancer International Research Group (BCIRG), Edmonton, AB, Canada.
The Art of Oncology - A decade's contribution and experience of the BCIRG in changing the breast cancer paradigm
_____________________________________
Following the merge of CIRG and TORI late 2005, they are now officially incorporated in a new structure named:
- Translate preclinical findings into clinical research
- Use translational approaches based on the underlying biology of the disease
- Conduct innovative clinical research across all phases of drug development and multiple disease sites
For more details on this new structure please access to the newly website: http://www.trioncology.org
_____________________________________
TORI (founded by Dr Dennis Slamon) is an oncology research network linked to several basic research laboratories which evaluate new therapeutic molecules.
TORI labs uses molecularly characterized models of various human malignancies to study new agents to guide the design of Phase I and Phase II Clinical Studies.
Once leading compounds are ready for larger studies, CIRG and its proven network of committed investigators can perform these larger translational trials.
____________________________________________________________
